Literature DB >> 6163805

Inhibition of cyclic AMP accumulation in hamster adipocytes with phosphatidic acid: differences and similarities with alpha adrenergic effects.

R J Schimmel, T W Honeyman, K K McMahon, R Serio, R B Clark.   

Abstract

Clark et al (Journal of Cyclic Nucleotide Research 6:37 (1980)) demonstrated phosphatidic acid inhibition of cyclic AMP formation in WI-38 fibroblasts and suggested the hypothesis that cholinergic inhibition of adenylate cyclase is mediated through accumulation of this phospholipid. In view of these data, we tested the hypothesis that phosphatidic acid is involved in alpha-adrenergic inhibition of cyclic AMP formation in hamster adipocytes. The effects of phosphatidic acid on hormone and methyl xanthine stimulated cyclic AMP accumulation and lipolysis were studied. Phosphatidic acid inhibited 3-isobutyl-1-methyl xanthine (IBMX) stimulated cyclic AMP formation. The maximum inhibition (85% to 100%) of IBMX stimulated cyclic AMP accumulation was detected at 1.0 microM phosphatidic acid. When lipolysis was measured, however, inhibitory effects of phosphatidic acid were not evident until the concentration of phospholipid was increased to 300 microM. The cyclic AMP lowering and antilipolytic effects were detected using egg yolk phosphatidic acid, dipalmitoyl phosphatidic acid, dimyristoyl phosphatidic acid, distearoyl phosphatidic acid and palmitoyl lysophosphatidic acid but not with phosphatidylinositol, phosphatidylserine, phosphatidylethanolamine, phosphatidylcholine or 1,2- diglyceride. In contrast to phosphatidic acid, clonidine or N6-phenylisopropyl adenosine inhibited lipolysis in concert with inhibition of methyl xanthine stimulated cyclic AMP accumulation. Cyclic AMP accumulation increased by isoproterenol in combination with IBMX was partially blocked by clonidine but not by phosphatidic acid. These results show similarities as well as differences between clonidine and phosphatidic acid actions on hamster fat cells and do not, therefore, provide unequivocal support for the possibility that phosphatidic acid is intimately involved in alpha-adrenergic effects on hamster adipocytes. However, the high selectivity of phosphatidic acid suggests a physiological role of this agent in regulation of adenylate cyclase.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6163805

Source DB:  PubMed          Journal:  J Cyclic Nucleotide Res        ISSN: 0095-1544


  8 in total

1.  Purification of a phosphatidic-acid-hydrolysing phospholipase A2 from rat brain.

Authors:  F J Thomson; M A Clark
Journal:  Biochem J       Date:  1995-02-15       Impact factor: 3.857

2.  Phosphatidic acid and phosphatidylinositol labelling in adipose tissue. Relationship to the metabolic effects of insulin and insulin-like agents.

Authors:  T W Honeyman; W Strohsnitter; C R Scheid; R J Schimmel
Journal:  Biochem J       Date:  1983-05-15       Impact factor: 3.857

3.  Phosphatidate-dependent protein phosphorylation.

Authors:  S B Bocckino; P B Wilson; J H Exton
Journal:  Proc Natl Acad Sci U S A       Date:  1991-07-15       Impact factor: 11.205

4.  Phosphatidic acid and phosphatidylinositol labelling in adipose tissue. The role of endogenously formed adenosine.

Authors:  R J Schimmel; T W Honeyman; K K McMahon
Journal:  Biochem J       Date:  1983-05-15       Impact factor: 3.857

5.  Adenylate cyclase is inhibited upon depletion of plasma-membrane cholesterol.

Authors:  A D Whetton; L M Gordon; M D Houslay
Journal:  Biochem J       Date:  1983-05-15       Impact factor: 3.857

6.  Adenosine effects on glucose oxidation of adipocytes isolated from streptozotocin-diabetic rats.

Authors:  E H Wong; J A Smith; L Jarett
Journal:  Biochem J       Date:  1985-11-15       Impact factor: 3.857

7.  Purification of a lysophosphatidic acid-hydrolysing lysophospholipase from rat brain.

Authors:  F J Thompson; M A Clark
Journal:  Biochem J       Date:  1994-06-01       Impact factor: 3.857

Review 8.  Targeting Lysophosphatidic Acid in Cancer: The Issues in Moving from Bench to Bedside.

Authors:  Yan Xu
Journal:  Cancers (Basel)       Date:  2019-10-10       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.